Actinic keratosis

ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225

Retrieved on: 
Wednesday, October 18, 2023

The joint venture will fulfill the unmet global manufacturing and production needs of this coveted radioisotope.

Key Points: 
  • The joint venture will fulfill the unmet global manufacturing and production needs of this coveted radioisotope.
  • The collaboration also encompasses the development and implementation of the manufacturing process to be used at the APF.
  • ITM will also be responsible for global marketing, sales, and distribution, which will be supported by its well-established global sales network.
  • “Working with ITM, CNL has already made significant progress towards our goal of bringing a next-generation medical radioisotope to the world market.

ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225

Retrieved on: 
Wednesday, October 18, 2023

The joint venture will fulfill the unmet global manufacturing and production needs of this coveted radioisotope.

Key Points: 
  • The joint venture will fulfill the unmet global manufacturing and production needs of this coveted radioisotope.
  • The collaboration also encompasses the development and implementation of the manufacturing process to be used at the APF.
  • ITM will also be responsible for global marketing, sales, and distribution, which will be supported by its well-established global sales network.
  • “Working with ITM, CNL has already made significant progress towards our goal of bringing a next-generation medical radioisotope to the world market.

Global Actinic Keratosis Market Insight, Epidemiology and Market Forecasts, 2018-2020 & 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 13, 2021

The "Actinic Keratosis Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Actinic Keratosis Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Actinic Keratosis (AK)-Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of the Actinic Keratosis, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The disease epidemiology covered in the report provides historical as well as forecasted Actinic Keratosis (AK) epidemiology segmented as the Total Prevalent Cases of Actinic Keratosis (AK), Sub-type Specific Prevalent cases of Actinic Keratosis, Gender Specific Prevalence of Actinic Keratosis.
  • The drug chapter segment of the Actinic Keratosis (AK) report encloses the detailed analysis of Actinic Keratosis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

Global Actinic Keratosis Epidemiology Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 3, 2021

The "Actinic Keratosis - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Actinic Keratosis - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The Actinic Keratosis epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries.
  • The disease epidemiology covered in the report provides historical as well as forecasted Actinic Keratosis epidemiology segmented as the Total Diagnosed Prevalence of Actinic Keratosis, Gender-based Prevalence of Actinic Keratosis, and Age-based Prevalence of Actinic Keratosis.
  • Actinic Keratosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
    Actinic Keratosis Epidemiology Report and Model provide an overview of the risk factors and global trends of Actinic Keratosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
    The report provides insight into the historical and forecasted patient pool of Actinic Keratosis in the seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
    The report provides the segmentation of the Actinic Keratosis epidemiology by Total diagnosed Prevalence of Actinic Keratosis, Prevalence of Actinic Keratosis based on Gender specific factors, Age-specific cases of Actinic Keratosis in 7MM
    What will be the growth opportunities in the 7MM concerning the patient population about Actinic Keratosis?

Global Actinic Keratosis Treatment Market 2021-2029 - Market Opportunities in the Lucrative Future for Light-based Treatments - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021

The actinic keratosis (AK) treatment market is anticipated to grow at a CAGR of about 4.5% during the forecast period 2021-2029.

Key Points: 
  • The actinic keratosis (AK) treatment market is anticipated to grow at a CAGR of about 4.5% during the forecast period 2021-2029.
  • Threat related with untreated actinic keratosis is 20% higher than treated actinic keratosis.
  • Whereas, lack of awareness related to actinic keratosis, is a major setback in the treatment of AK.
  • The reasons for growth of AK treatment market in North American and European actinic keratosis market are advanced healthcare infrastructure, awareness among people related to the disease and its treatment, high income, favourable regulatory framework and reimbursements.

Almirall delivers robust H1 performance and increases full-year guidance

Retrieved on: 
Monday, July 26, 2021

BARCELONA, Spain, July 26, 2021 /PRNewswire/ -- Almirall, S.A. (BME: ALM), the global biopharmaceutical company based in Barcelona, has announced its H1 2021 financial results.

Key Points: 
  • I am very confident about the direction of the company and its performance.
  • Almirall continues developing an extensive EU rollout campaign supported by long-term data that confirms Ilumetri's efficacy and safety profile.
  • Full year Core Guidance updated.Core Net Sales* mid-single-digit growth, Core EBITDA** between 195 - 215 MM (previously between 190 - 210 MM).
  • [ii] Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective.

Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis

Retrieved on: 
Monday, July 19, 2021

This approval by the European Commission marks another significant milestone for Klisyri, shortly following the marketing approval and launch of Klisyri in the U.S., said Dr. Johnson Lau, Chief Executive Officer of Athenex.

Key Points: 
  • This approval by the European Commission marks another significant milestone for Klisyri, shortly following the marketing approval and launch of Klisyri in the U.S., said Dr. Johnson Lau, Chief Executive Officer of Athenex.
  • In December 2020, Athenex received approval from the U.S. Food and Drug Administration (FDA) for the commercialization of Klisyri (tirbanibulin) in the U.S. for the topical treatment of AK of the face or scalp.
  • Our partner Almirall led the U.S. launch of Klisyri in February and is leading the launch of Klisyri in Europe.
  • Klisyri (tirbanibulin) is a microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) of the face or scalp.

Almirall receives European Commission approval of Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis

Retrieved on: 
Monday, July 19, 2021

BARCELONA, Spain, July 19, 2021 /PRNewswire/ -- Almirall S.A. (BME: ALM), a global biopharmaceutical company, announced today that the European Commission (EC) has approved Klisyri (tirbanibulin) for the topical treatment of actinic keratosis (AK) on the face or scalp in adults.

Key Points: 
  • BARCELONA, Spain, July 19, 2021 /PRNewswire/ -- Almirall S.A. (BME: ALM), a global biopharmaceutical company, announced today that the European Commission (EC) has approved Klisyri (tirbanibulin) for the topical treatment of actinic keratosis (AK) on the face or scalp in adults.
  • "The approval of Klisyrirepresents a breakthrough for actinic keratosis patients, who seek for new treatments that could offer them a better tolerability and short treatment duration.
  • In addition, Almirall has submitted Klisyri for a marketing authorisation in Switzerland in Q4 2020 and the dossier is currently under review by Swissmedic.
  • [4]Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective.

Almirall receives European Commission approval of Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis

Retrieved on: 
Monday, July 19, 2021

"The approval of Klisyrirepresents a breakthrough for actinic keratosis patients, who seek new treatments that could offer them better tolerability and short treatment duration.

Key Points: 
  • "The approval of Klisyrirepresents a breakthrough for actinic keratosis patients, who seek new treatments that could offer them better tolerability and short treatment duration.
  • In addition, Almirall submitted Klisyri for a marketing authorisation in Switzerland in December 2020 and the dossier is currently under review by Swissmedic.
  • The company has already submitted in Great Britain via the European Commission Decision Reliance Procedure.
  • Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective.

Skin Cancer Drugs Global Market Report 2021: Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma - ResearchAndMarkets.com

Retrieved on: 
Friday, June 25, 2021

Major players in the global skin cancer drugs market are Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, and Sun Pharmaceutical Industries Ltd.

Key Points: 
  • Major players in the global skin cancer drugs market are Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, and Sun Pharmaceutical Industries Ltd.
  • The skin cancer drugs market consists of sales of skin cancer drugs.
  • Skin cancer can be of various types including actinic keratoses, basal cell carcinoma, squamous cell carcinoma or melanoma.
  • To treat such high cases of skin cancer, more number of new innovative skin cancer drugs is being manufactured.